The IQVIA name became effective as of Nov. 6, the company said. Plans call for IQVIA equity shares to trade on the New York Stock Exchange under the ticker symbol “IQV” starting on Nov. 15. Until then, the company will continue to be listed under QuintilesIMS and symbol “Q” on the NYSE.
QuintilesIMS was formed in October 2016 with the completion of the merger of IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The companies announced their agreement to merge in May 2016.
“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive health care forward. Our clients have been instrumental in our becoming IQVIA,” stated Ari Bousbib, chairman and chief executive officer of IQVIA.
“IMS Health and Quintiles came together because our clients were asking for better, faster ways to bring innovations to patients and capture the improvements the industry has been pursuing for years,” Bousbib explained. “Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings. Our vision is to outpace the inevitable progress of change across the life sciences and accelerate our ability to empower healthcare decision makers to meet the future head on.”
IQVIA has about 55,000 employees in more than 100 countries. The company said its insights and execution capabilities aim to help biotech, medical device and pharmaceutical firms, medical researchers, government agencies, payers and other health care stakeholders gain a deeper understanding of diseases, human behaviors and scientific advances, pushing them farther along their path toward cures.
Client solutions are powered by the IQVIA CORE, which the company said enables it to provide customized solutions for clients leveraging the world’s largest curated health care information source, advanced analytics, leading technologies and extensive industry knowledge across diseases, geographies and scientific methods. These capabilities drive IQVIA’s approach to human data science, including faster, more predictable clinical development, innovative approaches to generating real-world evidence, machine learning to improve patient care, and strategies for precision commercial engagement, according to the company.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.